PROPECIA (finasteride)
Propecia helps men who are experiencing male pattern hair loss, a condition also known as androgenetic alopecia. It is used to manage hair thinning by lowering specific hormone levels in the scalp and blood. This medication is intended for use in men only and has not been shown to be effective for hair loss at the temples.
How PROPECIA Works
This medication works by blocking Type II 5-alpha reductase, an enzyme responsible for converting testosterone into dihydrotestosterone (DHT). By inhibiting this process, the drug reduces the high levels of DHT found in the scalp tissues of men with male pattern hair loss. Lowering these DHT concentrations helps address the miniaturization of hair follicles associated with the condition.
Details
- Status
- Prescription
- First Approved
- 1997-12-19
- Routes
- ORAL
- Dosage Forms
- TABLET
PROPECIA Approval History
What PROPECIA Treats
1 indicationsPROPECIA is approved for 1 conditions since its original approval in 1997. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Androgenetic Alopecia
Merck's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Clinical Trial Registry
18 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06944145 | 2025P000440 R01DK142211 | Ph 2 | recruiting | New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia |
| NCT02703220 | PULM-008-14F | Ph 4 | recruiting | Sleep Apnea in Elderly |
| NCT01227993 CSC-Ext results posted | 110012 11-EI-0012 | Ph 1, Ph 2 | completed | Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy |
| NCT00736645 results posted | CDR0000611962 RPCI I 104607 | Ph 2 | completed | Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer |
| NCT02248701 results posted | B1449-R 1I01RX001449-01A1 | Ph 2 | terminated | Testosterone Plus Finasteride Treatment After Spinal Cord Injury |
| NCT02548117 | 03-15-40-10 | Ph 3 | withdrawn | H-36731: Finasteride in Management of Elevated Red Blood Cells |
| NCT03004469 results posted | PM1541 | Ph 3 | completed | Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia |
| NCT02781311 results posted | 1922-201-002 | Ph 2 | completed | A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males |
| NCT01534351 results posted | 0906A-149 | Ph 3 | terminated | Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2) |
| NCT00564460 | E-2007 | Ph 3 | withdrawn | On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP) |
| NCT01296672 results posted | ROI 10-352H R01CA138627 | Ph 4 | completed | 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer |
| NCT00837252 results posted | 090075 09-EI-0075 | Ph 1, Ph 2 | completed | Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy |
| NCT00542243 Prostress | 07-0499-B | Ph 3 | completed | A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy |
| NCT01585441 results posted | 120119 12-EI-0119 | Ph 2 | terminated | Finasteride for Chronic Central Serous Chorioretinopathy |
| NCT00600691 | H07-01188 Health Canada Control #118638, Merck Frosst #IISP #P2587 | Ph 2 | terminated | The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy |
| NCT01139762 results posted | 13529 H6D-CR-LVIW | Ph 3 | completed | A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms |
| NCT00663793 ORAL-T-6 results posted | 33738-B U54HD42456-06, K23HD045386 | Ph 1 | completed | ORAL T-6: Oral Androgens in Man-6 |
| NCT01052870 | HairDx2009 | Ph 1 | completed | Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PROPECIA FDA Label Details
Indications & Usage
FDA Label (PDF)PROPECIA is indicated for the treatment of Androgenetic Alopecia.
Track PROPECIA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.